Earnings summaries and quarterly performance for LivaNova.
Executive leadership at LivaNova.
Board of directors at LivaNova.
BS
Brooke Story
Detailed
Director
DZ
Donald Zurbay
Detailed
Director
DS
Dr. Sharon O’Kane
Detailed
Director
FB
Francesco Bianchi
Detailed
Director
JC
J. Christopher Barry
Detailed
Director
PW
Peter Wilver
Detailed
Director
SE
Stacy Enxing Seng
Detailed
Director
SP
Susan Podlogar
Detailed
Director
TS
Todd Schermerhorn
Detailed
Director
WK
William Kozy
Detailed
Chair of the Board
Research analysts who have asked questions during LivaNova earnings calls.
Adam Maeder
Piper Sandler Companies
4 questions for LIVN
Also covers: ABT, AXNX, EW +13 more
DR
David Rescott
Baird
4 questions for LIVN
Also covers: HAE, INSP, IRTC +7 more
DR
David Roman
Goldman Sachs Group Inc.
4 questions for LIVN
Also covers: ABT, BAX, BDX +18 more
FW
Frederick Wise
Stifel
3 questions for LIVN
Also covers: AORT, ATRC, AVNS +13 more
Michael Polark
Wolfe Research
3 questions for LIVN
Also covers: BSX, DXCM, EMBC +11 more
Matthew Miksic
Barclays PLC
2 questions for LIVN
Also covers: ABT, ATEC, BAX +15 more
Michael Matson
Needham & Company
2 questions for LIVN
Also covers: AORT, ATRC, CNMD +22 more
AP
Anthony Petrone
Mizuho Group
1 question for LIVN
Also covers: ADMA, ALC, BSX +22 more
MT
Matthew Taylor
Jefferies
1 question for LIVN
Also covers: ALUR, BDX, CQP +18 more
Matt Miksic
Barclays Investment Bank
1 question for LIVN
Also covers: ABT, ATEC, BAX +14 more
MT
Matt Taylor
Jefferies & Company Inc.
1 question for LIVN
Also covers: BAX, BIO, DXCM +10 more
MS
Michael Sarcone
Jefferies
1 question for LIVN
Also covers: ALC, AXGN, CTSO +11 more
Mike Polark
Wolfe Research, LLC
1 question for LIVN
Also covers: BBNX, BSX, DXCM +6 more
RW
Rick Wise
Stifel Financial Corp
1 question for LIVN
Also covers: BDX, BSX, GEHC +8 more
Recent press releases and 8-K filings for LIVN.
LivaNova Outlines Strategic Growth Plan and Financial Targets
LIVN
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- LivaNova reported $1.3 billion in revenue in the last 12 months as of September of last year, achieving 10% organic revenue growth and 17% EPS growth over the past 11 quarters.
- The company projects a high single-digit plus revenue CAGR and low double-digit to mid-teens EPS CAGR from 2025 to 2030, with adjusted operating income margin in the high 20s by 2030.
- LivaNova is strategically entering the obstructive sleep apnea (OSA) market, anticipating $200-$400 million in OSA revenue with 80%+ gross margin and 25%+ adjusted operating margin by 2030, and expects the OSA P&L to break even by 2029.
- A significant upside opportunity exists in the difficult-to-treat depression (DTD) market, potentially unlocking a billion-plus dollar market if CMS grants reimbursement, though this is not included in current long-term financial projections.
- Recent positive updates include a nearly 50% increase in Medicare reimbursement for VNS Therapy procedures in the epilepsy business, effective January 1st of this year, and positive clinical data for CORE-VNS and RECOVER study durability in DTD.
6 days ago
LivaNova Details Growth Strategy and Financial Outlook
LIVN
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- LivaNova projects a high single-digit plus revenue CAGR and low double-digit to mid-teens EPS CAGR from 2025 to 2030, expecting to exit with an adjusted operating income margin in the high 20s.
- The company anticipates a 50% increase in Medicare reimbursement for VNS Therapy procedures in its epilepsy business, effective January 1st of this year, which is expected to improve hospital economics and drive procedure penetration.
- LivaNova plans a full commercial launch for its Obstructive Sleep Apnea (OSA) device in H2 2027, targeting $200-$400 million in revenue and over 25% adjusted operating margin by 2030, with the OSA P&L breaking even by 2029.
- A significant upside opportunity exists in difficult-to-treat depression (DTD) with VNS Therapy, pending a CMS reimbursement decision, which is not currently included in the company's long-range financial plan.
6 days ago
LivaNova outlines strategic growth plan and financial projections through 2030
LIVN
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- LivaNova reported $1.3 billion in revenue for the last 12 months as of September of last year, achieving 10% organic revenue growth and 17% EPS growth over the past 11 quarters.
- The company is strategically expanding into the obstructive sleep apnea (OSA) market, with a full commercial launch anticipated in the second half of 2027, projecting OSA revenue between $200 million and $400 million and an adjusted operating margin of 25% plus by 2030.
- Recent positive developments include a significant increase of nearly 50% in CMS reimbursement for VNS Therapy procedures in epilepsy, effective January 1st of this year, which is expected to boost procedure volumes and hospital economics.
- LivaNova's long-range plan (2025-2030) forecasts high single-digit plus revenue CAGR, adjusted operating income margin in the high 20s, and a low double-digit to mid-teens EPS CAGR.
6 days ago
LivaNova Discusses 2025 Outlook, Long-Range Plan, and Key Product Launches
LIVN
Guidance Update
Product Launch
New Projects/Investments
- LivaNova expects to achieve 9.5%-10.5% full-year growth for 2025 and projects mid- to high-single-digit top-line and EPS growth for its 2025-2028 Long-Range Plan, targeting a 20% operating margin.
- The company anticipates a significant 40%-50% increase in facility reimbursement for VNS Therapy (de novo implants and replacements) effective January 1, 2026, which is expected to remove economic barriers for hospitals and drive volume.
- Key product developments include the launch of the Essence Air Manager and a new heater/cooler in 2026, a next-generation IPG for epilepsy in 2027, and a next-generation oxygenator in 2028.
- For Obstructive Sleep Apnea (OSA), LivaNova targets $200 million-$400 million in revenue by 2030, with a next-generation device launching in late 2027 following heavy R&D investment in early 2026 and the recent hiring of a global head of commercialization.
Dec 2, 2025, 6:30 PM
LivaNova Discusses 2025 Outlook, 2026 Growth Drivers, and Key Product Developments
LIVN
Guidance Update
Product Launch
New Projects/Investments
- LivaNova projects 9.5%-10.5% full-year growth for 2025, with mid-to-high single-digit revenue and adjusted EPS growth targeted for 2025-2028, aiming for a 20% operating margin.
- Effective January 1, 2026, facility reimbursement for de novo VNS implants will increase by 40%-50%, eliminating the current $10,000-$15,000 average loss per procedure for hospitals and potentially unlocking significant volume.
- The company plans to launch new hardware for its Heart-Lung Machine (HLM) in 2026 and a next-generation oxygenator in 2028, targeting 45% oxygenator market share by 2030.
- LivaNova is heavily investing in R&D for its next-generation Obstructive Sleep Apnea (OSA) device, targeting $200 million-$400 million in OSA revenue by 2030, with a soft launch in H1 2027 and full launch in H2 2027.
Dec 2, 2025, 6:30 PM
LivaNova outlines strategic transformation and growth targets across key businesses
LIVN
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- LivaNova is executing a portfolio transformation to achieve durable, accelerated top and bottom-line growth by shifting towards larger, faster-growing, and more profitable markets.
- The company forecasts mid-single-digit growth for its epilepsy business through 2030, supported by core innovation, improved reimbursement (CMS upgrade for replacement devices to level five), and the upcoming launch of a cloud platform in 2026 for remote titration.
- LivaNova expects mid to high single-digit growth in its cardiopulmonary business over the next three to five years, driven by the SNs upgrade cycle and significant oxygenator market share gains, including 10 share points in the last two years and a target of an additional 800 basis points.
- A new strategic focus on the sleep apnea (OSA) market aims for $200 million to $400 million in revenue by 2030, leveraging a device with 15 years of battery life and a novel Polysync titration algorithm.
- The company forecasts mid to high single-digit revenue and EPS CAGR from 2025 to 2028, followed by 25% earnings growth in the subsequent years, while maintaining an annual AOI margin of 20%, reflecting a "generational investment cycle" in sleep apnea.
Nov 17, 2025, 7:40 PM
LivaNova outlines portfolio transformation, growth strategies, and financial targets
LIVN
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- LivaNova is pursuing a portfolio transformation to achieve durable, accelerated growth in faster-growing and more profitable markets.
- The company projects mid-single-digit growth for its Epilepsy business, with low single-digit growth for replacement devices and mid to high single-digit growth for new patients.
- For the Cardiopulmonary business, LivaNova forecasts mid to high single-digit growth over the next three to five years, aiming for an additional 800 basis points of market share gains in oxygenators after gaining 10 share points in the last two years.
- LivaNova is making a significant investment in the Sleep Apnea market, expecting it to contribute $200 million to $400 million in revenue by 2030, leveraging its neuromodulation capabilities.
- The company's five-year vision for EPS growth includes a mid to high single-digit CAGR from 2025 to 2028, followed by 25% earnings growth in subsequent years, while maintaining an annual AOI margin of 20%.
Nov 17, 2025, 7:40 PM
LivaNova Outlines Growth Strategy and Financial Targets
LIVN
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- LivaNova is undergoing a portfolio transformation to achieve durable, accelerated growth, targeting mid to high single-digit revenue and EPS CAGR over 2025-2028 while maintaining an annual AOI Margin of 20%. This strategy includes significant investments in new growth areas.
- The company forecasts mid-single-digit growth for its epilepsy business through 2030, driven by refocusing on core innovation, improved reimbursement (including a recent CMS upgrade to Level Five for replacement devices), and clinical evidence. A cloud platform for remote titration is planned for launch in 2026.
- LivaNova expects mid to high single-digit growth over the next three to five years in its cardiopulmonary business, supported by its market leadership, the SNs upgrade cycle, and a target of an additional 800 basis points of oxygenator market share gains.
- LivaNova is entering the sleep apnea (OSA) market, projecting $200 million to $400 million in revenue by 2030 from this segment. This move is seen as an opportunity to enter a larger, faster-growing, and more profitable market, leveraging existing neuromodulation capabilities and differentiated clinical data.
Nov 17, 2025, 7:40 PM
LivaNova Presents 2030 Financial Targets and Strategic Plan
LIVN
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- LivaNova PLC hosted its 2025 Investor Day, outlining a strategic roadmap and long-range financial plan with 2030 targets including a high-single-digit-plus revenue compound annual growth rate (CAGR), low double-digit to mid-teens earnings-per-share CAGR, adjusted annual operating margin above 20% over the next three years targeting high twenties by 2030, and adjusted free cash flow conversion above 80%.
- The company's strategy is built on maximizing its core Cardiopulmonary and Epilepsy businesses, scaling Obstructive Sleep Apnea (OSA), and preserving upside in Difficult-to-Treat Depression (DTD).
- The Obstructive Sleep Apnea (OSA) business is projected to generate $200 million to $400 million in revenue by 2030, achieve an adjusted operating income margin of greater than 25%, and is expected to be break-even by 2029 following planned commercialization in 2027.
- Difficult-to-Treat Depression (DTD) is considered a significant upside option, though it is not included in the long-range financial projections due to pending coverage reconsideration with the U.S. Centers for Medicare & Medicaid Services (CMS).
Nov 12, 2025, 8:26 PM
LivaNova Outlines Strategic Vision and Financial Targets at Investor Day
LIVN
Guidance Update
New Projects/Investments
Management Change
- LivaNova highlights its strong core Epilepsy and Cardiopulmonary businesses, which are market-leading and generate steady growth and strong cash. The Cardiopulmonary segment has achieved double-digit revenue and adjusted operating income growth for 11 consecutive quarters.
- The company is focused on transformative growth opportunities in Obstructive Sleep Apnea (OSA), a $1.0 billion market with double-digit CAGR, and has upside optionality with its Depression Treatment Device (DTD).
- LivaNova reported $1.3 billion in LTM Revenue and set 2025E-2030E financial targets including a high single-digit+ Revenue CAGR, maintaining >20% Adjusted Operating Margins through 2028 (reaching high 20s by 2030), and a low double-digit to mid-teens Adjusted EPS CAGR.
- The company has a refreshed leadership team with key appointments in 2024 and 2025, including Vladimir Makatsaria as CEO.
Nov 12, 2025, 2:00 PM
Quarterly earnings call transcripts for LivaNova.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more